**The Impact of the Covid-19 Pandemic on the Resistance Level of *Mycobacterium tuberculosis* in Suspected Tuberculosis Patients**

**at the Surakarta Central General Hospital**

**Yusup Subagio Sutanto1), Magdalena Sutanto**2)**, Agnes Sri Harti3)**

1)Department of Pulmonology and Respiratory Medicine, Faculty of Medicine,

Sebelas Maret University, Surakarta

2)Surakarta Regional General Hospital, Surakarta Indonesia

3)Department of Nursing, Faculty of Health Sciences, Kusuma Husada University, Surakarta Indonesia

**Abstract**

**Background:** Analysis of the impact of the Covid-19 pandemic on the resistance level of *Mycobacterium tuberculosis* (MTb) isolates to Anti Tuberculosis Drugs (ATD) needs to be carried out considering the level of MTB resistance is an important factor in the occurrence of Multidrug-Resistant TB (MDR-TB) in Indonesia. The purpose of the study was to analyze the impact of the Covid-19 pandemic on the level of resistance of MTb isolates of patients with suspected TB in the Surakarta area.

**Subjects and Method:** This research is a quantitative descriptive study with a retrospective Cohort based on the medical record data of suspected TB patients at Surakarta Central General Hospital in 2020 – 2021. The sampling technique was random sampling with a total of 200 samples each year. Data analysis used the SPSS 21 program.

**Results:** Characteristics of respondents with suspected TB patients who visited the Surakarta Central General Hospital in 2020 and 2021, mostly in men and occurring in productive ages 36-55 years. The most effective type of ATD against MTb isolates is Rifampicin with a mean rank of 6.00 and a p-value=0.035. While Ethambutol is ineffective as an ATD with a mean rank of 58.00 and a p-value=0.000. The results of the Wilcoxon test analysis showed there was a significant difference in the level of resistance or sensitivity of MTb isolates in 2020 and 2021 with a mean rank of 44.50 and a p-value=0.000.

**Conclusion:** There is a significant effect of the impact of the Covid-19 pandemic on the level of resistance or sensitivity of MTb isolates of patients with suspected TB in the Surakarta area in 2020 and 2021.

**Keywords:** pandemic, Covid-19, resistance, MTb isolates, ATD

**Correspondence:**

Yusup Subagio Sutanto. Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Sebelas Maret University, Surakarta. Jl. Kolonel Sutarto 132, Surakarta 57126, Central Java, Indonesia. Email: [yusupsubagiosutanto@gmail.com](mailto:yusupsubagiosutanto@gmail.com). Mobile: +62811284165

**BACKGROUND**

This part must contain strong rationale for the author to have conducted the current research. The author must formulate the research question and refer the theories that are used to address the research question. This part ends with a statement of the study objective. Coronavirus disease 2019 (Covid-19) is an acute respiratory syndrome caused by Coronavirus 2 (SARS-CoV-2) known as a global pandemic and the Covid-19 case in Indonesia occurred in early March 2020. The Covid-19 pandemic had an impact on all aspects of life. aspects directly and or indirectly to various other infections including TB. The latest data on October 21, 2021, shows that there are 301 cases of TB in Indonesia per 100,000 population, placing Indonesia in the 3rd position with the most TB cases globally.

The World Health Organization said that TB cases increased again globally in the midst of the Covid-19 pandemic and it was estimated that the Covid-19 pandemic had worsened the situation for TB sufferers, in addition to health funds being diverted to deal with Covid-19 and difficult access to care due to the lockdown. As a result, there is a decrease in the number of people seeking TB preventive treatment by 2.8 million in 2020, or a decrease of about 21% compared to 2019. The target of a world free from the TB epidemic in 2030 can be reduced to 80 percent, it is feared that it will not be achieved due to the Covid-19 pandemic (WHO, 2020).

The distribution of the rate of TB and MDR-TB in Indonesia is influenced by various factors that contribute to the occurrence of germ resistance to ATD, including respondent characteristics, treatment programs, culture, socio-economic and environmental conditions including the impact of the Covid-19 pandemic. The initial Covid-19 case in Indonesia was detected in March 2020 with various causes of the Coronavirus variant until it was updated, namely the Omicron delta type. From April 2021 to date, the Government of Indonesia has intensively implemented a national and free vaccination program for all Indonesians through the 1st and 2nd vaccination programs, and even now, a booster program is still being implemented to prevent the spread of Covid-19.

Prolonged MDR-TB therapy can have side effects, namely a correlation between the cure rate and changes in the bacterial profile related to resistance to ATD. Based on data from the Ministry of Health of the Republic of Indonesia in 2020, only 271,750 TB cases were found in Indonesia. This number decreased sharply when compared to 2019 which was 568,987 cases. In fact, the estimated number of TB cases in Indonesia in 2020 is around 840,000. It is estimated that there will be an addition of 6.3 million cases and 1.4 million deaths of TB patients in the world during 2020-2025 with an achievement of 65 cases per 100 thousand population and a decrease in mortality to 6 per 100 thousand population in 2030 (Ministry of Health RI, 2020).

Research on the analysis of the development of resistance levels of MTb isolates in patients with suspected TB who visited the Surakarta Central General Hospital as a result of the Covid-19 pandemic and the vaccination program has been carried out by the Indonesian Government nationally, needs to be done considering the level of resistance is an important factor in the occurrence of MDR-TB in Indonesia. Based on this, the general objective of the study is to analyze the impact of the Covid-19 pandemic on the resistance level of MTb isolates of patients suspected of having TB in the Surakarta area from March 2020 to December 2021.

**SUBJECTS AND METHOD**

1. **Study Design**

The data collection technique was based on medical record data of suspected TB patients who visited the Surakarta Central General Hospital from March 2020 to December 2021.

1. **Population and Sample**

The sampling technique was random sampling with a total sampling of 200 samplings every year.

1. **Study Variables**

The independent variable was the type of ATD including Streptomycin, Isoniazid, Rifampicin, and Ethambutol (SIRE), while the dependent variable was the level of resistance or sensitivity of MTb isolates.

1. **Study Instruments**

MTb isolates were obtained based on the results of a positive MTB screening test based on laboratory examinations including the Molecular Rapid Test (TCM) and Drug Susceptibility Testing (DST) from suspected TB patients who visited the Surakarta Central General Hospital for the period from March 2020 to December 2021.

1. **Data analysis**

The primary data, the editing stage was carried out, coding, scoring, and tabulating for further statistical analysis, namely univariate and bivariate analysis to determine the relationship between the independent variable and the dependent variable with a significance level of = 0.05. Data analysis used the SPSS version 21 program.

**RESULTS**

1. **Characteristics of Respondents**

Characteristics of respondents from the medical records of suspected TB patients who visited the Surakarta Central General Hospital from March 2020 to December 2021 as listed in table 1.

**[Table 1 should be positioned here]**

1. **Effectiveness of ATD against MTb Isolate Resistance or Sensitivity**

The results of the research related to the effectiveness of the types of ATD namely Streptomycin, Isoniazid, Rifampicin, and Ethambutol (SIRE) used at the Surakarta Central General Hospital against MTb isolates for the period March 2020 to December 2021 as listed in table 2.

**[Table 2 should be positioned here]**

1. **Distribution of MTb isolate Resistance or Sensitivity Levels**

The distribution of the description of the level of resistance or sensitivity of MTb isolates during the period March 2020 to December 2021 at the Surakarta Central General Hospital is listed in table 3.

**[Table 3 should be positioned here]**

**DISCUSSION**

Based on table 1 shows the characteristics of the respondents by gender, the most suspected TB patients in 2020 were male as many as 125 people (62.5%), and in 2021 as many as 110 people (55.0%). The characteristics of respondents based on age are at most 36-45 and 46-55 years old as many as 45 people (22.5%) in 2020 and 46-55 years old as many as 49 people (24.5%) in 2021. The incidence of TB can be influenced by factors of age, gender, nutritional status, education level, socioeconomic and lifestyle, including smoking habits. TB infection is more common in men because smokers are generally dominated by men as a result, men are more easily exposed to the risk of TB. Smoking habits can reduce the immunity of smokers because of the toxins in cigarettes that are harmful to health, namely tar, nicotine, CO, and NO gases from tobacco so that the person becomes more susceptible to MTB bacterial infection. The results of research conducted in 2016-2017 at the Surakarta Hospital showed that TB cases in men occurred 1.5–1.9 times more compared in women (Sutanto, 2021c).

The results showed that the age of the respondents was dominated by adults and productive ages, namely 36-55 years. Age as an independent factor in the incidence of MDR-TB. Productive age to adulthood is the respondent's optimum activity age-related to work activities and socio-economic conditions. The distribution of TB patients generally shows that more than at 50% occur at productive ages, namely 20-50 years, this is related to the social relations and working conditions of the respondents (Lu et al, 2017). The level of resistance to ATD in respondents aged over 60 years and reinfection cases showed significantly lower in other than age groups due to an imbalance of drug resistance between different age groups, mainly due to medication history (Ullah et al, 2016; Lan et al, 2016). 2019). The 45-64 year age group has a significant 2.4 times risk with the incidence of drug-resistant TB compared to the 15-24 year age group (Farihatun, 2018).

The distribution of the occurrence of MTB and MDR-TB in patients with suspected TB is influenced by various factors that contribute to the occurrence of bacterial resistance to drugs, characteristics of respondents, treatment programs, culture, socio-economics, and the environment. Variables that affect the incidence of MDR-TB include family support, knowledge, regularity of taking medication, and the role of health workers. In addition, TB patients who do not regularly take ATD are at risk of 11218 times experiencing MDR-TB. The knowledge of pulmonary TB patients about TB disease, the required treatment, and the length of treatment that must be carried out affect the patient's adherence to complete treatment. Patients with low levels of knowledge will be at risk of treatment failure more than twice compared to patients who have high knowledge. Respondents with poor medication adherence had a risk of 2486 times MDR-TB disease compared to respondents who adhered to taking ATD in TB treatment. Factors of education, knowledge, behavior, social support, and self-efficacy of TB patients are related to the level of adherence to treatment of TB patients (Muhammad, 2019).

Diagnosis of drug-resistant TB (TB-RO), MDR-TB, and XDR-TB can be done using TCM with PCR (Xpert MTB/RIF) methods, culture examination, and DST. DST is an in vitro susceptibility test method for M. tuberculosis as one of the laboratory diagnostic parameters used in determining the level of bacterial resistance. DST is performed after the results of a positive smear microscopic examination or a positive TCM examination result. DST uses Lowenstein Jensen (LJ) solid media containing in vitro (Harti et al, 2018). The ideal examination method is to meet the criteria of specificity, sensitivity, and representativeness so that each method has advantages and disadvantages. The results of the sample culture are part of the sensitivity test of M. tuberculosis to drugs and determine the potential for MDR-TB (Lu et al, 2018).

TB can be cured by giving the right ATD, however, recently many MTB strains have been found to be resistant to two or more ATDs known as MDR-TB strains (Kemenkes RI, 2018). TB treatment lasts quite a long time, namely at least 6 months of treatment, making patients drop out of treatment or take treatment irregularly. Both of these things have fatal consequences, causing treatment to fail and the bacteria to become resistant, known as MDR, which results in multiple costs and makes it more difficult to treat TB for the sake of eradicating TB in Indonesia.

Based on the data in table 2 shows that in 2020 and 2021 shows that the most effective type of ATD against MTb isolates is Rifampicin, namely in 2020 only 2 MTb isolates (1%) were resistant and in 2021 there were 9 resistant MTb isolates (4.5%) with a mean rank = 6.00 and a p-value = 0.035. While Ethambutol is ineffective as an ATD, in 2020 there were 143 resistant MTb isolates (71.5%) and in 2021 there were 72 resistant MTb isolates (36.0%) with a mean rank = 58.00 and a p-value of 0.000. The varying levels of resistance or sensitivity of MTb isolates to ATD were influenced by several factors, including the different characteristics of respondents related to the level of TB infection from respondents who suspected early TB or the MDR-TB group. MDR-TB is one type of MTB resistance to at least two first-line antiretroviral drugs, namely isoniazid and rifampin, the two most effective antiretroviral drugs. The effectiveness of ATD against MTb isolates was also influenced by the biomolecular mycolic acid resistance gene (trehalose dimycolate) which functions equivalently to lipopolysaccharide in Gram-negative bacterial cells. The presence of mycolic acid content in MTB plays an important role in the level of resistance of bacteria to host immune cells and drugs; namely inhibiting the fusion of macrophages in host cells against pathogens. Initial treatment of pulmonary TB caused by MTB usually uses isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EB) or streptomycin (SM) as the mainstay. Resistance encourages the use of alternative drugs that are more toxic, namely ethionamide, aminosalicylic acid, cycloserine, capreomycin, ciprofloxacin, or ofloxacin (Kobayashi, 2017).

Many factors contribute to the resistance of bacteria to drugs and the occurrence of MDR-TB. Resistance of MTb isolates to ATD can be in the form of primary resistance and secondary resistance. Resistance of germs to ATD can occur if the administration of drugs is not appropriate namely the patient does not complete the treatment given, health workers provide inappropriate treatment in terms of combination, dose, duration of treatment, and quality of drugs, as well as problems with the supply of drugs that are not always available (Sun et al, 2019).

MDR-TB is a TB infection caused by MTB and is resistant in vitro to isoniazid (H) and rifampin with or without other drug resistance (Li et al, 2018). The emergence of M. tuberculosis strains that are resistant to two or more ATD causes the failure rate of tuberculosis therapy to be high (Wu et al, 2019). The use of natural ingredients-based galenic preparations has potential as an alternative to ATD therapy. The results showed that the combination of snail seromucoid and chitosan has potential as a bioimmunostimulator and bioimmunodulator in TB therapy (Sutanto et al, 2020; Sutanto, 2021a, 2021b). Durian peel extract polysaccharides and chitosan have the potential to an antimicrobial against MTb isolates (Sutanto et al, 2022).

Determination of the incidence rate of MDR-TB and MTB is a useful determinant for early and accurate detection of mortality rates and the effectiveness of therapy in TB patients. Early detection of MDR-TB and starting therapy as early as possible are important factors for achieving successful therapy. The existence of side effects in MDR-TB therapy and the correlation between cure rates and ATD resistance requires a social psychological management approach in MDR-TB patients and the need to know the profile of MTB bacteria related to ATD resistance (Migliori et al, 2020). The most dominant variable influencing the incidence of MDR-TB is medication adherence; therefore, it is necessary to improve the outreach program to patients and families about the importance of medication adherence and the consequences arising from non-adherence to taking medication so that this can be used to control the increase in the incidence of MDR-TB (Ama, 2020). The results showed that the distribution of the incidence of MDR-TB and MTB in 2016 and 2017 at the Surakarta Central General Hospital was relatively varied. In 2016 the percentage of MDR-TB (45.21%) was lower than MTB (54.79%) while in 2017 the incidence rate of MDR-TB (76.14%) was higher than MTB (23.86%) (Sutanto et al, 2020).

The presence of resistance factors from MTB bacteria to the effectiveness of the ATD used can affect the incidence of MTB and MDR-TB in an area. Therefore, predictions or indicators of the determinants of the incidence of MDR-TB in TB patients, including the characteristics and risk factors that make a person susceptible to early detection of TB disease, are important factors for achieving the success of TB therapy on the mortality rate and effectiveness of therapy in patients. TB. To achieve this, a number of strategies were carried out by the Ministry of Health Republic Indonesia assisted by related institutions through 3 things namely prevention, detection, and therapy. The preventive strategy is carried out by increasing BCG immunization in children which have been carried out so far. BCG coverage in the last 3 years has decreased in achievement due to the impact of the Covid-19 pandemic, namely in 2018 as much as 37%, in 2019 as much as 50%, and in 2020 as much as 32%. The detection strategy includes the availability of laboratory inspection facilities at the community health center or Hospital level, namely the molecular rapid test (TCM) examination which is constrained because not every community health center has this equipment with data there are 1,168 TCM devices spread over 34 provinces and 496 regencies and cities. The detection strategy can also be carried out through tracing per village, sub-district to the province of patients with suspected TB. While the therapeutic strategy is carried out by administering an appropriate anti-tuberculosis drug regimen (ATD), considering that TB treatment includes long-term treatment related to the profile of MTb bacteria which has unique physiology in the cell wall and the emergence of MDR-Tb strains (Li et al. 2018).

Based on table 3 shows that the resistance level of MTb isolates decreased from 79.5% in 2020 and 58.5% in 2021 or inversely proportional to the sensitivity level of MTb isolates which increased from 20.5% in 2020 to 41.5% in 2021. The results of the Wilcoxon test analysis showed mean rank of 44.50 and a p-value 0.000 so there was a significant difference in the level of resistance or sensitivity of MTb isolates in 2020 with 2021. Based on the results of this study, the resistance level of MTb isolates in 2021 tends to decrease compared to that of 2015. 2020 while the sensitivity of MTb isolates tends to increase. The decrease or increase in this percentage cannot be used as a guideline or reference that MDR-TB cases are lower than MTB due to various factors that affect the rate of MDR-TB in an area. The decrease in MTb isolates resistance was possible because of the Covid-19 vaccination program as immunoprophylaxis which had an impact on increasing the immune system of probands or MTB patients, namely bioimmunomodulators, thereby suppressing the resistance of MTb isolates. The emergence of MDR-TB can be caused by comorbid factors or other comorbidities, including HIV, PTM infection, metabolic disorders; non-adherence to taking medication due to the relatively long TB treatment period of 6 months, and environmental conditions related to the epidemiology of the impact of the Covid-19 pandemic.

This result is a problem that should be observed during the period of the Covid-19 pandemic case that appeared in Indonesia in March 2020 and reached a peak on July 14, 2021, and the vaccination program in Indonesia began to be run nationally on January 13, 2021. Coronavirus disease 2019 (Covid-19) or acute respiratory syndrome caused by Coronavirus 2 (SARS-CoV-2), is a global pandemic, including in Indonesia. Symptoms and signs of Covid-19 include pneumonia, lymphopenia, lymphocyte deficit, and the occurrence of a cytokine storm that results in acute respiratory distress which can ultimately lead to death. Detection of Coronavirus infection can be carried out based on the patient's clinical profile (signs and symptoms) and laboratory diagnosis results, including lung x-rays, hematology, rapid antigen or antibody tests, measurement of IgM, and IgG antibodies, PCR (Polymerase Chain Reaction). Cytokine storm profile plays an important role in the Covid-19 infection process. The results of research by Zhao et al (2020) on 463 patients with Covid-19 showed a decrease in the number of total lymphocytes, CD3+, CD4+, and CD8+ in T lymphocytes resulting in lethal pneumonia.

TB cases that have not been found have a very high transmission potential, such as Covid-19. There are similarities and differences between TB and Covid-19, namely, transmission can occur through droplets and the location of the infection in the respiratory tract, but the differences are in terms of etiology, symptoms, pathogenesis, diagnosis, and different ways of handling. The etiology of TB is the bacterium Mycobacterium tuberculosis, the etiology of Covid-19 is the Coronavirus or known as SARS-Cov2. Symptoms of TB include onset or chronic attack of more than 14 days with symptoms of fever less than 38oC accompanied by coughing up phlegm, blood spots, gradually worsening shortness of breath, weight loss, and night sweats. Meanwhile, the symptoms of Covid-19 include acute onset symptoms of less than 14 days accompanied by a fever of more than 38oC with dry cough, shortness of breath appearing immediately after onset, joint pain, runny nose, headache, impaired smell or taste. The TB and Covid-19 diagnosis processes have similarities, namely using the TCM and Polymerase Chain Reaction (PCR) methods, but the difference is in the sampling. For the diagnosis of Covid-19, you must go through a swab, while TB is enough with phlegm. TB treatment uses the ATD regimen that already exists and has been developed to date, while for Covid-19 there is currently no cure, and is still in the exploration stage as a Covid-19 drug. Control of Covid-19 infection can be carried out through the application of the 5M health protocol, namely wearing masks, washing hands, maintaining distance, staying away from crowds and limiting mobility, chemotherapy using effective anti-virus drugs, and increasing body immunity, and vaccination programs. The vaccination program related to the Covid-19 pandemic intensified by the Government of Indonesia, which began in 2021 until now, aims to improve the body's immune system, which has an impact on the occurrence of a person's herd immunity.

The limitations of the study are the number of samples that are not the same every year and it is not possible to know the effect of vaccination on the level of MTb isolate resistance because there is no medical record data from patients suspecting TB whether they have carried out a complete vaccination program or not. Therefore, it is recommended for further research related to the effect of the vaccination program on the resistance level of MTb isolates due to the Covid-19 pandemic.

The conclusion of the study was that the characteristics of the respondents suspected of TB who visited the Surakarta Central General Hospital in 2020 and 2021, mostly men and occurred in the productive age of 36-55 years. The most effective type of ATD against MTb isolates was Rifampicin, while Ethambutol was ineffective as an ATD. The results of the Wilcoxon test analysis showed a p-value = 0.000 so there was a significant effect of the impact of the Covid-19 pandemic on the resistance level or sensitivity of MTb isolates from 2020 to 2021.

**Financial support and sponsorship**

None

**ACKNOWLEDGEMENT**

The authors contributed to drafting, research design, data analysis, and discussion.

**AUTHOR'S CONTRIBUTION**

The authors contributed to drafting, research design, data analysis, and discussion

**CONFLICT OF INTEREST**

There was no conflict of interest in this study.

**REFERENCE**

Ama PGB, Suhermi, Fradilla F (2020). The influence of clinical factors and regularity of taking medication with the occurrence of MDR TB in the working area of ​​the Pasar Rebo District Health Center. East Jakarta. Scientific Journal of Health, 12(1):16-29. DOI:https://doi.org/10.37012/jik.v12i1.115

Farihatun S, Machmud PB (2018). Determinant factors of drop out (DO) among multi-drug resistance tuberculosis (MDR-TB) patients at Jakarta Province in 2011 to 2015. Indonesian. Journal of Tropical and Infectious Disease, 7(3): 87–92. https:// doi.org/ 10.20473/ijtid.v7i3.7793.

Harti AS, Murharyati A, Sulisetyawati SD, Oktariani M (2018). The effectiveness of snail mucus (*Achantina fulica*) and chitosan towards lymphocyte proliferation in vitro. Asian Journal Pharmaceutical and Clinical Research, 11(3): 85-8. DOI 10.22159/ ajpcr.2018.v11s3.30041

Indonesian Ministry of Health (2020). National strategic plan of tuberculosis control 2016-2020.

Indonesian Ministry of Health (2018). Tuberculosis. Jakarta

Kobayashi N, Hattori T, Akter S, Mizoue T, Ohta K (2017). Treatment outcomes in patients with multidrug-resistant tuberculosis in Japan, 2011-2013. European Respiratory Journal, 50(suppl61), <https://doi.org/10.1183/1393003.congress-2017.PA3494>

Lan Y, Li, Y, Chen L, Zhang J, Zhang H (2019). Drug resistance profiles and trends in drug-resistant tuberculosis at a major hospital in Guizhou Province of China. infected. Drug Resistant. 12: 211–19. doi: 10.2147/IDR.S188538

Li Q, Zhao G, Wu L, Lu M, Liu W, Wu Y (2018). Prevalence and patterns of drug resistance among pulmonary tuberculosis patients in Hangzhou, China. antimicrobial. resistance. infected. Control 7: 61. doi:10.1186/s13756-018-0348-7.

Li Y, Cao X, Li S, Wang H, Wei J, Liu P (2016). Characterization of *Mycobacterium tuberculosis* isolates from Hebei, China: genotypes and drug susceptibility phenotypes. BMC Infect. Dec. 16:107. doi:10.1186/s12879-016-1441-2.

Liu Y, Zhang X, Zhang Y, Sun Y, Yao C, Wang W (2018). Characterization of *Mycobacterium tuberculosis* strains in Beijing, China: drug susceptibility phenotypes and Beijing genotype family transmission. BMC Infect. Dec. 18: 658. doi: 10.1186/s12879-018-3578-7.

Lu P, Liu Q, Martinez L, Yang H, Lu W, Ding X, Zhu L (2017). Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. European Respiratory Journal, 49(3):1–4. <https://doi.org/10.1183/13993003.01558-2016>.

Migliori GB, Simon T, Alimuddin Z, Eskild P, Jeremiah MC, Christian W, Marcela MT, et al. (2020). MDR/XDR-TB management of patient and contacts: Challenges faacing the new decade. The 2020 clinical update by the global tuberculosis network. International Journal of Infectious Diseases, 92: S15-S25, International Society for Infectious Diseases. DOI: https://doi.org/ 10.1016/ j.ijid.2020.01.042.

Muhammad M, Fadli F (2019). Analysis of the causative factors of Multi - Drug Resistance (MDR) in tuberculosis patients. Indonesian Journal of Public Health Publications, 6(2): 62-7. DOI: <http://dx.doi.org/10.20527/jpkmi.v6i2.7454>.

Sun F, Li Y, Chen Y, Guan W, Jiang X, Wang X, et al. (2019). Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study. European Respiratory Journal, 53(3), 1801770. DOI: 10.1183/13993003.01770-2018.

Sutanto YS, Sutanto M, Harti AS, Puspawati N (2020). The sensitivity test of *Mycobacterium tuberculosis* isolates from suspect tuberculosis patients to the seromucous of snail and chitosan as an alternative anti-tuberculosis drugs. Asian Journal of Pharmaceutical and Clinical Research, 13(10), 44-9. https:// doi.org/10.22159/ajpcr.22020.v22113i22110.38266

Sutanto YS, Sutanto M, Harti AS, Puspawati N (2021a). The potential of snail seromucous and chitosan as bioimmunomodulator for tuberculosis therapy. Sains Malaysiana 50 (11) 2021: 3159-3169. http://doi.org/10.17576/jsm-2021-5011-01 .

Sutanto YS, Sutanto M, Harti AS, Puspawati N (2021b). The sensitivity test of *Mycobacterium tuberculosis* to snail seromucoid and chitosan in vitro. Biomedicine 14(1): 36-46. https://doi.org/10.31001/ biomedika.v14i1.1128

Sutanto YS, Sutanto M, Harti AS (2021c). Anti-tuberculosis drugs against the resistance level of *Mycobacterium tuberculosis* isolates KEMAS, 17 (1) 14-23. https:// doi.org/ 10.15294/kemas.v11i1.24158

Sutanto YS, Sutanto M, Harti AS, Puspawati N (2022). The antimicrobial effectiveness of chitosan and polysaccharide of durian peel extract against *Mycobacterium tuberculosis* isolates. Open Access Macedonian Journal of Medical Sciences, 9(A):326-33. <https://doi.org/10.3889/oamjms.2022.8088>

Ullah I, Javaid A, Tahir Z, Ullah O, Shah AA, Hasan F, et al. (2016). Pattern of drug resistance and risk factors associated with development of drug resistant *Mycobacterium tuberculosis* in Pakistan. PLoS ONE 11(1): e0147529. https:// doi.org/ 10.1371/ journal.pone.0147529.

World Health Organization (2018). Global Tuberculosis Report 2018. Available online at: <https://www.who.int/tb/publications/global_report/en/>

Wu X, Yang J, Tan G, Liu H, Liu Y, Guo Y, Gao R, Wan B, Yu, F (2019). Drug resistance characteristics of *Mycobacterium tuberculosis* isolates from patients with tuberculosis to 12 antituberculous drugs in China. Frontiers In Cellular And Infection Microbiology, 9, 345. [https://doi.org/10.3389/fcimb.2019. 00345](https://doi.org/10.3389/fcimb.2019.%2000345).

Yao Z, Zheng Z, Wu K, Zheng J (2020). Immune environment modulation in pneumonia patients caused by Coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2. Aging 12, (9): 7639-51.

Zhao J, Yuan Q, Wang H, et al. (2019). Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis. 2020;71(16):2027-2034. doi:10.1093/cid/ciaa344

**Table 1. Distribution of respondent’s characteristics**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristics** | **2020 Year** | | **2021 Year** | |
| **Frequency** | **Percentage** | **Frequency** | **Percentage** |
| **Gender** |  |  |  |  |
| Male | 125 | 62.5% | 110 | 55.0% |
| Female | 75 | 37.5% | 90 | 45.0% |
| **Age** |  |  |  |  |
| < 18 years old | 2 | 1.0% | 2 | 1.0% |
| 18-25 years old | 29 | 14.5% | 21 | 10.5% |
| 26-35 years old | 24 | 12.0% | 30 | 15.0% |
| 36-45 years old | 45 | 22.5% | 44 | 22.0% |
| 46-55 years old | 45 | 22.5% | 49 | 24.5% |
| 56-65 years old | 38 | 19.0% | 40 | 20.0% |
| > 65 years old | 17 | 8.5% | 14 | 7.0% |

**Table 2. The level of effectiveness of ATD against MTb isolates in 2020-2021**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Type of ATD** | **2020 Year** | | | | | **2021 Year** | | | | ***Mean***  ***Rank*** | ***P -value*** |
| **R** | **%** | **S** | **%** | **R** | | **%** | **S** | **%** |
| S (Streptomycin) | 108 | 54.0 | 92 | 46.0 | 70 | | 35.0 | 130 | 65.0 | 55.50 | 0.000 |
| I (Isoniazid) | 50 | 25.0 | 150 | 75.0 | 14 | | 7.0 | 186 | 93.0 | 30.50 | 0.000 |
| R (Rifampicin) | 2 | 1.0 | 198 | 99.0 | 9 | | 4.5 | 191 | 95.5 | 6.00 | 0.035 |
| E (Ethambutol) | 143 | 71.5 | 57 | 28.5 | 72 | | 36.0 | 128 | 64.0 | 58.00 | 0.000 |

Note: R = Resistance, S = Sensitivity

**Table 3.** **Distribution of resistance and sensitivity of MTb isolates in 2020-2021**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Description** | **2020 Year** | | **2021 Year** | | ***Mean***  ***Rank*** | ***P -value*** |
| **Total** | **%** | **Total** | **%** |
| Resistance | 159 | 79.5 | 117 | 58.5 | 44.50 | 0.000 |
| Sensitivity | 41 | 20.5 | 83 | 41.5 |